Cargando…

Aspects of innate immunity in Sjögren's syndrome

Previously, a dominant role of the adaptive immune system in the pathogenesis of Sjögren's syndrome was suspected. Recent advances, however, have revealed a major role of the type I IFN pathway, documented by an increased circulating type I IFN activity and an IFN 'signature' in perip...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Hui Zhi, Witte, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218872/
https://www.ncbi.nlm.nih.gov/pubmed/21635716
http://dx.doi.org/10.1186/ar3318
_version_ 1782216746851106816
author Low, Hui Zhi
Witte, Torsten
author_facet Low, Hui Zhi
Witte, Torsten
author_sort Low, Hui Zhi
collection PubMed
description Previously, a dominant role of the adaptive immune system in the pathogenesis of Sjögren's syndrome was suspected. Recent advances, however, have revealed a major role of the type I IFN pathway, documented by an increased circulating type I IFN activity and an IFN 'signature' in peripheral blood mononuclear cells and minor salivary gland biopsies from the patients. Polymorphisms in the genes IRF5 and STAT4 leading to increased IFN activation are associated with disease susceptibility. In the pathogenesis of Sjögren's syndrome, the activation of salivary gland epithelial cells appears to be the initial event. Once intrinsically activated, they express costimulatory and Toll-like receptors (TLRs) and MHC class I and II molecules, can present autoantigens and produce proinflammatory cytokines. The subsequent activation of plasmacytoid dendritic cells induces the production of high levels of proinflammatory cytokines in individuals with the risk alleles of the susceptibility genes IRF5 and STAT4. Under the influence of the high IFN concentration in the glands and through TLR ligation, B-cell activating factor is produced by epithelial cells and, together with autoantigen presentation on salivary gland epithelial cells, stimulates the adaptive immune system. In view of the central role of IFNalpha in at least the initiation of the pathogenesis of Sjögren's syndrome, blockade of this cytokine may be a rational therapeutic approach.
format Online
Article
Text
id pubmed-3218872
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32188722011-11-27 Aspects of innate immunity in Sjögren's syndrome Low, Hui Zhi Witte, Torsten Arthritis Res Ther Review Previously, a dominant role of the adaptive immune system in the pathogenesis of Sjögren's syndrome was suspected. Recent advances, however, have revealed a major role of the type I IFN pathway, documented by an increased circulating type I IFN activity and an IFN 'signature' in peripheral blood mononuclear cells and minor salivary gland biopsies from the patients. Polymorphisms in the genes IRF5 and STAT4 leading to increased IFN activation are associated with disease susceptibility. In the pathogenesis of Sjögren's syndrome, the activation of salivary gland epithelial cells appears to be the initial event. Once intrinsically activated, they express costimulatory and Toll-like receptors (TLRs) and MHC class I and II molecules, can present autoantigens and produce proinflammatory cytokines. The subsequent activation of plasmacytoid dendritic cells induces the production of high levels of proinflammatory cytokines in individuals with the risk alleles of the susceptibility genes IRF5 and STAT4. Under the influence of the high IFN concentration in the glands and through TLR ligation, B-cell activating factor is produced by epithelial cells and, together with autoantigen presentation on salivary gland epithelial cells, stimulates the adaptive immune system. In view of the central role of IFNalpha in at least the initiation of the pathogenesis of Sjögren's syndrome, blockade of this cytokine may be a rational therapeutic approach. BioMed Central 2011 2011-05-27 /pmc/articles/PMC3218872/ /pubmed/21635716 http://dx.doi.org/10.1186/ar3318 Text en Copyright ©2011 BioMed Central Ltd
spellingShingle Review
Low, Hui Zhi
Witte, Torsten
Aspects of innate immunity in Sjögren's syndrome
title Aspects of innate immunity in Sjögren's syndrome
title_full Aspects of innate immunity in Sjögren's syndrome
title_fullStr Aspects of innate immunity in Sjögren's syndrome
title_full_unstemmed Aspects of innate immunity in Sjögren's syndrome
title_short Aspects of innate immunity in Sjögren's syndrome
title_sort aspects of innate immunity in sjögren's syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218872/
https://www.ncbi.nlm.nih.gov/pubmed/21635716
http://dx.doi.org/10.1186/ar3318
work_keys_str_mv AT lowhuizhi aspectsofinnateimmunityinsjogrenssyndrome
AT wittetorsten aspectsofinnateimmunityinsjogrenssyndrome